http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Kim, Taeho,Momin, Eric,Choi, Jonghoon,Yuan, Kristy,Zaidi, Hasan,Kim, Jaeyun,Park, Mihyun,Lee, Nohyun,McMahon, Michael T.,Quinones-Hinojosa, Alfredo,Bulte, Jeff W. M.,Hyeon, Taeghwan,Gilad, Assaf A. American Chemical Society 2011 JOURNAL OF THE AMERICAN CHEMICAL SOCIETY - Vol.133 No.9
<P/><P>Mesoporous silica-coated hollow manganese oxide (HMnO@mSiO<SUB>2</SUB>) nanoparticles were developed as a novel <I>T</I><SUB>1</SUB> magnetic resonance imaging (MRI) contrast agent. We hypothesized that the mesoporous structure of the nanoparticle shell enables optimal access of water molecules to the magnetic core, and consequently, an effective longitudinal (<I>R</I><SUB>1</SUB>) relaxation enhancement of water protons, which value was measured to be 0.99 (mM<SUP>−1</SUP>s<SUP>−1</SUP>) at 11.7 T. Adipose-derived mesenchymal stem cells (MSCs) were efficiently labeled using electroporation, with much shorter <I>T</I><SUB>1</SUB> values as compared to direct incubation without electroporation, which was also evidenced by signal enhancement on <I>T</I><SUB>1</SUB>-weighted MR images in vitro. Intracranial grafting of HMnO@mSiO<SUB>2</SUB>-labeled MSCs enabled serial MR monitoring of cell transplants over 14 days. These novel nanoparticles may extend the arsenal of currently available nanoparticle MR contrast agents by providing positive contrast on <I>T</I><SUB>1</SUB>-weighted images at high magnetic field strengths.</P>
Use of adipose-derived stem cells in lymphatic tissue engineering and regeneration
Forte, Antonio Jorge,Boczar, Daniel,Sarabia-Estrada, Rachel,Huayllani, Maria T.,Avila, Francisco R.,Torres, Ricardo A.,Guliyeva, Gunel,Aung, Thiha,Quinones-Hinojosa, Alfredo Korean Society of Plastic and Reconstructive Surge 2021 Archives of Plastic Surgery Vol.48 No.5
The potential to differentiate into different cell lines, added to the easy and cost-effective method of extraction, makes adipose-derived stem cells (ADSCs) an object of interest in lymphedema treatment. Our study's goal was to conduct a comprehensive systematic review of the use of ADSCs in lymphatic tissue engineering and regeneration. On July 23, 2019, using PubMed/MEDLINE, Cochrane Clinical Answers, Cochrane Central Register of Controlled Trials, and Embase databases, we conducted a systematic review of published literature on the use of ADSCs in lymphatic tissue engineering and regeneration. There were no language or time frame limitations, and the following search strategy was applied: ((Adipose stem cell) OR Adipose-derived stem cell)) AND ((Lymphedema) OR Breast Cancer Lymphedema). Only original research manuscripts were included. Fourteen studies fulfilled the inclusion criteria. Eleven studies were experimental (in vitro or in vivo in animals), and only three were clinical. Publications on the topic demonstrated that ADSCs promote lymphangiogenesis, and its effect could be enhanced by modulation of vascular endothelial growth factor-C, interleukin-7, prospero homeobox protein 1, and transforming growth factor-β1. Pilot clinical studies included 11 patients with breast cancer-related lymphedema, and no significant side effects were present at 12-month follow-up. Literature on the use of ADSCs in lymphatic tissue engineering and regeneration demonstrated promising data. Clinical evidence is still in its infancy, but the scientific community agrees that ADSCs can be useful in regenerative lymphangiogenesis. Data collected in this review indicate that unprecedented advances in lymphedema treatment can be anticipated in the upcoming years.